Successful management of small cell neuroendocrine carcinoma of the ureter with neoadjuvant chemotherapy and adjuvant chemoradiation: case report and literature review

Author:

Farooq MudasirORCID,Daniel SherinORCID,Joel Anjana,Thampi John Nirmal

Abstract

Neuroendocrine tumours (NETs) of the urinary tract are rare, and the urinary bladder is the the most common primary site. Primary ureteric NET is rarer with under 80 cases reported in the literature thus far. Most of these tumours are of the high-grade small cell neuroendocrine carcinoma subtype, which has a worse prognosis. Neoadjuvant chemotherapy has a proven role in the management of NET of the bladder as it downstages the tumour, which may add to significant recurrence-free survival and overall survival. We report the successful management of a patient with locally advanced small cell neuroendocrine carcinoma of the ureter, who had a pathological complete response after neoadjuvant chemotherapy with etoposide and cisplatin. He subsequently received adjuvant chemotherapy followed by radiation and is recurrence-free at a follow-up of 1 year.

Publisher

BMJ

Subject

General Medicine

Reference22 articles.

1. Small cell carcinoma of the upper urinary tract (UUT-SCC): Report of a rare entity and systematic review of the literature

2. Atypical carcinoid neuroendocrine tumor of the ureter: a case report and literature review;Yuen;Surg J,2018

3. Systematic review and two new cases of primary upper urinary tract neuroendocrine carcinomas;Nakasato;Cancer Treat Res Commun,2018

4. Neuroendocrine carcinoma of the ureter: a case report and literature review;Wang;Oncol Lett,2016

5. Walther PJ . Adjuvant/neo-adjuvant etoposide/cisplatin and cystectomy for management of invasive small cell carcinoma of the bladder. J Urol 2002;167:285 https://scholar.google.com/scholar_lookup?journal=J+Urol&title=Adjuvant/neo-adjuvant+etoposide/cisplatin+and+cystectomy+for+management+of+invasive+small+cell+carcinoma+of+the+bladder&author=PJ+Walther&volume=167&publication_year=2002&pages=285&pmid=11743341&

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3